

VAS2870

Catalog No: tcsc0012525



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

722456-31-7

Formula:

$C_{18}H_{12}N_6OS$

Pathway:

Others

Target:

Others

Purity / Grade:

>98%

Solubility:

DMSO : 83.3 mg/mL (231.14 mM; Need ultrasonic)

Observed Molecular Weight:


360.39

Product Description

VAS2870 is a **NADPH oxidase (NOX)** inhibitor.

IC50 & Target: Target: NADPH oxidase^[1]

In Vitro: VAS2870 is effective to suppress PDGF-BB-dependent activation of NADPH oxidase and subsequent production of intracellular ROS. Furthermore, VAS2870 suppresses PDGF-BB-dependent chemotaxis, but not DNA synthesis. Preincubation with VAS2870 (10 and 20 μ M) completely abolishes PDGF-mediated NADPH oxidase activation and ROS production. Preincubation with VAS2870 (0.1-20 μ M) does not affect PDGF-induced cell cycle progression. However, it abolishes PDGF-dependent chemotaxis of VSMC in a concentration-dependent manner (100% inhibition at 10 μ M)^[1]. VAS2870 inhibits dose-dependently autocrine increase of cell number in FaO rat hepatoma cells, and almost completely blocked ROS production and thymidine incorporation when used at 25 mM. VAS2870 blocks serum-dependent cell growth of FaO rat hepatoma cells. VAS2870 inhibits proliferation of different human hepatocellular carcinoma (HCC) cell lines. VAS2870 pretreatment enhances TGF- β -mediated apoptosis of FaO rat hepatoma cells^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!